糖苷酶 F (PNGase F)酶活定義（UnitDefinition）1個(gè)酶活力單位指在10μL的反應(yīng)體系中，37℃條件下1小時(shí)從10μg變性RNaseB中除去超過(guò)95%的碳水化合物所需要的酶量。儲(chǔ)存條件-25~-15℃保存，有效期1年。使用方法1、變性條件下蛋白質(zhì)去糖基化：1）在水中加入1μLBuffer1和目標(biāo)糖蛋白（1-20μg），至終體積10μL；2）100℃溫度下煮沸10min使其變性，冰上冷卻，離心10秒；加入2μL的Buffer2、2μL的10％NP-40、6μL去離子水，總反應(yīng)體積20μL；加入1-2μL的PNGase，輕輕混勻。在37℃孵育1-3h。2、非變性條件下蛋白質(zhì)去糖基化：1）在水中加入2μL的Buffer2和目標(biāo)糖蛋白（1-20μg）至體積為20μL。2）加入2~5μL的PNGaseF,輕輕混勻。3）37°C孵育4-24h。注意：在變性條件下大多數(shù)底物能夠更好的去糖基化，在非變性條件下可能需要增加PNGaseF的量和延長(zhǎng)孵育時(shí)間。注意事項(xiàng)1.PNGaseF建議搭配我司提供的配套緩沖液使用，按我司說(shuō)明書建議的操作量配套緩沖液足夠。如您由于使用體系造成配套緩沖液不足，可咨詢當(dāng)?shù)劁N售進(jìn)行購(gòu)買（FGF-21）是FGF基因家族的成員。 基于其結(jié)構(gòu)，F(xiàn)GF-21與FGF-19和-23一起進(jìn)一步分為FGF的亞家族。Recombinant Human TIE1 Protein,His Tag

Recombinant Biotinylated Human MSLN/Mesothelin Protein,hFc-Avi Tag分子別名（Synonyms）Mesothelin;CAK1;MSLN;MPFSMRP表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）BiotinylatedHumanMSLN/MesothelinProteinisexpressedfromHEK293withhFctagandAvitagattheC-Terminus.ItcontainsGlu296-Gly580.[Accession|Q13421-2]分子量大?。∕olecularWeight）TheproteinhasapredictedMWof61.1kDa.Duetoglycosylation,theproteinmigratesto70-80kDabasedonSDS-PAGEresult.（Endotoxin）Lessthan1EUperμgbytheLALmethod.純度（Purity）>95%asdeterminedbySDS-PAGEandHPLC.活性（Activity）ELISAData:ImmobilizedAnti-MSLNAntibody,hFcTagat1μg/ml(100μl/well)ontheplate.DoseresponsecurveforBiotinylatedHumanMSLN,hFcTagwiththeEC50of18.4ng/mldeterminedbyELISA.Recombinant Mouse GPA33/A33 Protein,His Tag[Tyr1]-MIF-1配方：溶解于20 mM PBS, pH 7.4, 130 mM NaCl溶液中，并經(jīng)0.22μm過(guò)濾后凍干而成。

Recombinant Biotinylated Human HLA-A*02:01&B2M&MAGE-A4 or MAGE-A8 (KVLEHVVRV) Monomer Protein,His-Avi Tag性能參數(shù)分子別名（Synonyms）MAGE-A4orMAGE-A8;MAGE-A4;MAGE-A8;表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）BiotinylatedHumanHLA-A*02:01&B2M&MAGE-A4orMAGE-A8(KVLEHVVRV)MonomerProteinisexpressedfromHEK293withHistagandAvitagattheC-Terminus.ItcontainsGly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)andKVLEHVVRVpeptide.[Accession|A0A140T913(HLA-A*02:01)&P61769(B2M)&KVLEHVVRV]分子量大?。∕olecularWeight）TheproteinhasapredictedMWof50.50kDa.Duetoglycosylation,theproteinmigratesto52-62kDabasedonSDS-PAGEresult.（Endotoxin）Lessthan1EUperμgbytheLALmethod.純度（Purity）>95%asdeterminedbySDS-PAGEandHPLC.制劑（Formulation）Suppliedas0.22μmfilteredsolutioninPBS(pH7.4).儲(chǔ)存條件Theproductshouldbestoredat-85~-65℃for1yearfromdateofreceipt.

CD30,又稱KI抗原和Tnfrsf8,是一種120kdaI型跨膜糖蛋白,屬于tnf受體超家族。成熟的人CD30由一個(gè)361AA細(xì)胞外域(ECD)和六個(gè)富含半胱氨酸的重復(fù),28AA跨膜段和188AA細(xì)胞質(zhì)域。相比之下,小鼠和大鼠CD30缺乏90AA的ECD,并且只包含三個(gè)富含半胱氨酸的重復(fù)。在ECD的共同區(qū)域內(nèi),人CD30與小鼠CD30和大鼠CD30的序列認(rèn)同率分別為53%和49%。人類CD30的交替剪接產(chǎn)生一個(gè)等形,包括細(xì)胞質(zhì)域的C132AA。CD30通常在抗原細(xì)胞和B細(xì)胞上表達(dá)。但是,它在霍奇金氏病(紅-斯特恩伯格細(xì)胞上)、其他淋巴瘤、慢性炎癥中,以及自體免疫。CD30與CD30配體/tnfsf8結(jié)合,TH細(xì)胞、單核細(xì)胞、粒細(xì)胞和髓質(zhì)胸腺上皮細(xì)胞上表達(dá)。產(chǎn)品性質(zhì)別名CD30;CD30KI-1;CD30Lreceptor;TNFRSF8;D1S166EKi-1;CD30KI-1工會(huì)編號(hào)P28908-1表達(dá)區(qū)間及表達(dá)系統(tǒng)重組的人CD30/Tnfrsf8蛋白表達(dá)于在C-端有標(biāo)記和AVI標(biāo)記的HK293細(xì)胞。它含有……。分子量大約41.3公里。由于糖基化,蛋白質(zhì)遷移到70-100kda基于三聯(lián)頁(yè)面結(jié)果。純度SDS-PAGE和高效液相色譜法測(cè)定的95%。eotaxin-2還具有抑制髓樣細(xì)胞增殖的能力，髓樣細(xì)胞增殖是Eotaxin不共有的生物學(xué)功能。

CD19蛋白在B細(xì)胞和體液免疫反應(yīng)中起著作用。成熟B細(xì)胞對(duì)抗原刺激、胚芽中心發(fā)育和抗體親和性成熟的反應(yīng)能力是必需的。CD19已成為血液學(xué)和實(shí)體的有前途的靶點(diǎn)。產(chǎn)品性質(zhì)同義詞CD19;B4;CVID3;Leu-12;MGC12802工會(huì)編號(hào)P15391來(lái)源生化重組人CD19蛋白表達(dá)于HK293細(xì)胞,標(biāo)記于C-端。它含有金屬1-Lys291。分子量重組cd19由283個(gè)氨基酸組成,預(yù)測(cè)分子質(zhì)量為31.6kda。純潔90%由社會(huì)發(fā)展秘書處----政策和兩性平等局確定。內(nèi)用Lal法測(cè)定每一種蛋白質(zhì)。公式化用0.22腔形過(guò)濾液對(duì)PBS進(jìn)行凍干。凍干前添加5%-8%海藻糖、甘露醇和0.01%TWEen80作為保護(hù)劑。重建離心管打開(kāi)前。建議將其重組為100克/毫升以上的濃度。在蒸餾水中溶解凍干蛋白。α-凝血酶（α-Thrombin）可以啟動(dòng)XIII因子和血小板，或者用作血管收縮劑。Recombinant Human GFRA3 Protein,His Tag

泛素化反應(yīng)可以修飾蛋白質(zhì)，調(diào)節(jié)蛋白質(zhì)降解。泛素化還影響蛋白質(zhì)體事件，如蛋白質(zhì)定位、活性和功能。Recombinant Human TIE1 Protein,His Tag

Angiotensin I Converting Enzyme (ACE-2), also called ACEH (ACE homologue), is a dimeric, zinc-dependent metalloprotease of the ACE family that also includes somatic and germinal ACE. ACE-2 mRNA is found at high levels in heart, testis, and kidney and at lower levels in a wide variety of tissues. ACE-2 is the SARS-CoV and SARS-CoV2 Spike protein receptor in vivo, functions catalytically as a carboxypeptidase to cleave several substrates including angiotensins I and II, and acts as a partner for B0AT1-family amino acid transporters. Through these functions, ACE-2 has been shown to be involved in several diseases including SARS, COVID19, acute lung injury, heart disease, liver and lung fibrosis, inflammatory lung disease, and cardiopulmonary disease . Full length ACE-2 protein includes an extracellular region composed of a single N-terminal peptidase domain and C-terminal collectrin-like domain (CLD), a transmembrane domain, and a short cytoplasmic tail. The N-terminal peptidase region is required for binding to SARS-CoV and SARS-CoV2 spike proteins, while the CLD contains a region that promotes dimerization and association with amino acid transporters.Recombinant Human TIE1 Protein,His Tag